These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 28267837)

  • 21. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.
    Toce MS; Chai PR; Burns MM; Boyer EW
    J Med Toxicol; 2018 Dec; 14(4):306-322. PubMed ID: 30377951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study.
    Meyer MC; Johnston AM; Crocker AM; Heil SH
    J Addict Med; 2015; 9(2):81-6. PubMed ID: 25622120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
    Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
    Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 32. Opioid dependence treatment: options in pharmacotherapy.
    Stotts AL; Dodrill CL; Kosten TR
    Expert Opin Pharmacother; 2009 Aug; 10(11):1727-40. PubMed ID: 19538000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Just call it "treatment".
    Friedmann PD; Schwartz RP
    Addict Sci Clin Pract; 2012 Jun; 7(1):10. PubMed ID: 23186149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
    Krawczyk N; Picher CE; Feder KA; Saloner B
    Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
    Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
    Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.
    Zweben JE; Sorensen JL; Shingle M; Blazes CK
    J Addict Med; 2021 Nov-Dec 01; 15(6):454-460. PubMed ID: 33323695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
    Newman RG; Gevertz SG
    J Addict Dis; 2011 Oct; 30(4):318-22. PubMed ID: 22026523
    [No Abstract]   [Full Text] [Related]  

  • 39. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.